Mike Lazur, Noesis vets form new agency, Lazur Hoyvald Goldstein Partners

Share this article:

Former Torre Lazur McCann Healthcare chief creative director Mike Lazur, and Commonhealth’s Noesis veterans Christian Hoyvald and Steven Goldstein joined forces to become managing partners of a new agency, Lazur Hoyvald Goldstein Partners.

The agency opened the doors to its offices this April in Bridgewater, NJ.

All three partners see brand-building as their principle goal and believe they have a “nice mixture” of backgrounds, the trio told MM&M during a recent phone interview.

Lazur started out as an art director and has been a creative director for most of his more than 30 years in the industry. Hoyvald spent 14 years on the client side, holding positions in senior brand management, finance and market research at Novartis, Bristol-Myers Squibb and Reliant Pharmaceuticals. Four years ago, he joined Noesis ultimately serving as its EVP, director of client services. Goldstein was SVP, creative director at Noesis and a member of the CommonHealth Management committee. He has worked on several award-winning campaigns throughout his 20-year career.

Of the four clients currently signed on with Lazur Hoyvald Goldstein, one is a large chain of diagnostic radiology centers, one is a manufacturer of globally marketed oral specimen collection and diagnostic devices, and another is a long-established manufacturer of prescription dermatological and surgical products.

Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.